DANVERS, Mass., June 30, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the recent publication of a ...

The Impella heart pump is a small pump that a healthcare professional can insert without surgery. It can help maintain blood flow in people who have CAD, are recovering from cardiogenic shock, or are ...

Comments on this technology were invited from clinical experts working in the field and relevant patient organisations. The comments received are individual opinions and do not represent NICE's view.

In a major breakthrough in cardiac care, doctors in Thiruvananthapuram have successfully performed the first Impella-assisted angioplasty in South Kerala, saving the life of a 38-year-old patient ...

ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed. In more than ...

DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed (Nasdaq: ABMD) for its Impella Low Profile Sheath. Compared to the ...

TCT 69: Impella use for fulminant myocarditis in cardiogenic shock: Analysis of the Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD) Receive the the latest news, research, and ...

The U.S. FDA posted notice of a medical device correction of Abiomed Inc.'s Impella series of left-side blood pumps because of the risk of perforation of the left ventricle during device placement.

Investigators for the DanGer trial are spreading the word on their plans to test Impella—notably, in a randomized, controlled fashion—in patients with acute MI complicated by cardiogenic shock (AMICS) ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...

A literature search was carried out for this briefing in accordance with the published process and methods statement. This briefing includes the most relevant and best publicly available evidence ...